Reuters logo
BRIEF-Bristol-Myers Squibb signs exclusive worldwide license agreement with Psioxus Therapeutics for NG-348
December 20, 2016 / 12:30 PM / in a year

BRIEF-Bristol-Myers Squibb signs exclusive worldwide license agreement with Psioxus Therapeutics for NG-348

Dec 20 (Reuters) - Bristol-Myers Squibb Co

* Bristol-Myers Squibb signs exclusive worldwide license agreement with Psioxus Therapeutics for NG-348, an “armed” oncolytic virus to address solid tumors

* Bristol-Myers Squibb Co says Psioxus eligible to receive up to $886 million in development and sales-based milestones, as well as royalties on net sales

* Bristol-Myers Squibb Co says Psioxus is also eligible to receive up to $886 million in development, regulatory and sales-based milestones, as well as royalties on net sale

* Under terms of agreement, Bristol-Myers Squibb will grant Psioxus a $50 million upfront payment

* Bristol-Myers Squibb Co says will also be responsible for providing Psioxus funding to support activities related to preclinical development of NG-348 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below